CELC FDA: approves gedatolisib with fulvestrant, with or without palbociclib, for hr-positive, her2-negative locally advanced or metastatic
CELC FDA: approves gedatolisib with fulvestrant, with or without palbociclib, for hr-positive, her2-negative locally advanced or metastatic breast cancer
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.